Braegen-02

Last updated

Braegen-02
Braegen-02.svg
Identifiers
  • 4-[6-oxo-2-(trifluoromethyl)-3H-pyrano[2,3-e]benzimidazol-8-yl]benzonitrile
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C18H8F3N3O2
Molar mass 355.276 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1C#N)C2=CC(=O)C3=C(O2)C4=C(C=C3)NC(=N4)C(F)(F)F
  • InChI=1S/C18H8F3N3O2/c19-18(20,21)17-23-12-6-5-11-13(25)7-14(26-16(11)15(12)24-17)10-3-1-9(8-22)2-4-10/h1-7H,(H,23,24)
  • Key:XWJPZCVKIGMYPF-UHFFFAOYSA-N

Braegen-02 is a small-molecule drug which acts as a potent and selective agonist of the tropomyosin receptor kinase B (TrkB). It is commonly referred to as CF3CN due to the CF3 and CN groups in its chemical structure, but this may cause confusion with the unrelated chemical trifluoroacetonitrile which has the chemical formula CF3CN. As with many TrkB agonists it was derived through modification of the natural product TrkB agonist 7,8-dihydroxyflavone, but it is more potent than earlier derivatives such as R13. It is under development as a potential treatment for neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease. [1] [2] [3] [4]

References

  1. ↑ Liao J, Chen C, Ahn EH, Liu X, Li H, Edgington-Mitchell LE, et al. (October 2021). "Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer's disease". Neuropharmacology. 197: 108737. doi:10.1016/j.neuropharm.2021.108737. PMC   8478860 . PMID   34343610.
  2. ↑ Kang SS, Wu Z, Liu X, Edgington-Mitchell L, Ye K (July 2022). "Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase". Neurotherapeutics. 19 (4): 1283–1297. doi:10.1007/s13311-022-01248-1. PMC   9587159 . PMID   35595958.
  3. ↑ Wang G, Han J, Meng X, Kang SS, Liu X, Sun YE, et al. (September 2023). "Zein-Based Nanoparticles Improve the Therapeutic Efficacy of a TrkB Agonist toward Alzheimer's Disease". ACS Chemical Neuroscience. 14 (17): 3249–3264. doi:10.1021/acschemneuro.3c00401. PMC   10734774 . PMID   37583253.
  4. ↑ Wang Y, Liang J, Xu B, Yang J, Wu Z, Cheng L (January 2024). "TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury". Life Sciences. 336: 122282. doi:10.1016/j.lfs.2023.122282. PMID   38008209.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.